It is not unlikely that it will be necessary to combine ALK inhibitors with other inhibitors/drugs that either target downstream pathways—targeting the PI3K-Akt-mTOR pathway appears to be an especially promising strategy—or that otherwise influence ALK degradation, ALK phosphorylation, and cancer cell proliferation and apoptosis in general. This evidence concerns the gene MTOR and cancer.